By Fineline Cube 
The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based YolTech Therapeutics, raising over 300 million yuan (≈ $45 million). The round also attracted Green Pine Capital Partners, Tianjin Venture, and Xinneng Ventures. Follow‑on commitments from K2 Venture Partners, Grand Flight Investment, and Decheng Capital pushed YolTech’s cumulative funding to above 575 million yuan.
Why This Matters
| Item | Detail |
|---|---|
| Capital Infusion | 300 m+ yuan (~$45 m) fuels continued pipeline development |
| Investor Mix | Global (AstraZeneca‑CICC) + domestic venture capital backing |
| Funding Milestone | Total > 575 m yuan, the highest for an in‑vivo gene‑editing biopharma |
YolTech’s Technological Edge
YolTech has positioned itself as the global leader in clinical‑stage in‑vivo gene‑editing drugs. Its platform hinges on messenger‑RNA (mRNA) coupled with lipid‑nanoparticle (LNP) delivery—a highly specific, non‑viral system that can edit genes directly within living cells.
- Four Active Pipelines – All have entered clinical trials, covering a range of monogenic disorders.
- mRNA‑LNP Delivery – Enables efficient, site‑specific gene editing with minimal off‑target effects.
- Clinical‑Stage Leadership – More in‑vivo gene‑editing candidates in human trials than any other company worldwide.
Market & Competitive Landscape
- Regulatory Progress – Several of YolTech’s candidates are in Phase 1/2 studies, with regulatory submissions underway in China and the U.S.
- Strategic Partnerships – The AstraZeneca‑CICC lead signals potential future collaboration with major pharma players.
- Investment Trend – The biotech sector is witnessing a surge in funding for next‑generation therapeutics; YolTech’s raise underscores confidence in mRNA‑LNP gene‑editing.
Future Outlook
With the Series B round complete, YolTech plans to accelerate pre‑clinical work, expand clinical cohorts, and pursue regulatory approvals across key markets. The funding also positions the company to explore beyond‑gene‑editing applications, such as mRNA‑based vaccines and immunotherapies.-Fineline Info & Tech